FLGT — Fulgent Genetics Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapSuper Stock

Annual income statement for Fulgent Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	422	993	619	289	283
Cost of Revenue
Gross Profit	332	777	367	104	107
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	136	317	440	485	367
Operating Profit	286	676	179	-196	-84
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	287	677	184	-174	-52
Provision for Income Taxes
Net Income After Taxes	215	503	142	-175	-43.8
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	214	507	143	-168	-42.7
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	214	507	143	-168	-42.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	9.04	16.4	4.71	-3.01	-1.2